Are the protective effects of 17beta-estradiol on splenic macrophages and splenocytes after trauma-hemorrhage mediated via estrogen-receptor (ER)-alpha or ER-beta?

J Leukoc Biol. 2006 Jun;79(6):1173-80. doi: 10.1189/jlb.0106029. Epub 2006 Mar 10.

Abstract

The depression in cell-mediated immune function following trauma-hemorrhage is shown to be restored by 17beta-estradiol (E2) administration. However, it remains unknown which of the two estrogen-receptors, (ER)-alpha or ER-beta, plays the predominant role in mediating the beneficial effects of E2. Female B57BL/J6 ER-beta(-/-) transgenic mice [knockout (KO)] and corresponding ovariectomized wild-type (WT) mice were subjected to laparotomy and hemorrhagic shock (35.0+/-5.0 mmHg for 90 min) and treated with E2 (50 microg/25 g) or ER-alpha agonist propyl pyrazole triol (PPT; 50 microg/25 g) following trauma-hemorrhage. Four hours after resuscitation, systemic cytokine concentrations and cytokine release by splenocytes and splenic macrophages were determined by cytometric bead array. Trauma-hemorrhage resulted in a significant increase in plasma tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6, and IL-10. In contrast, the release of these cytokines by splenic macrophages was decreased significantly in WT and KO animals. Administration of E2 or PPT following trauma-hemorrhage produced a significant reduction in systemic TNF-alpha and IL-6 concentrations in WT and KO mice. Although the suppression in the productive capacity of these cytokines following trauma-hemorrhage by macrophages and splenocyte was also prevented in E2- and PPT-treated WT mice, the release of cytokines by macrophages and splenocytes in E2- and PPT-treated KO mice was not restored to the levels observed in sham animals. These findings collectively suggest that both receptors appear to play a significant role in mediating the immunoprotective effects of E2 in different tissue compartments following trauma-hemorrhage.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Concanavalin A / pharmacology
  • Cytokines / blood
  • Cytokines / metabolism
  • Estradiol / pharmacology
  • Estradiol / therapeutic use*
  • Estrogen Receptor alpha / agonists
  • Estrogen Receptor alpha / deficiency
  • Estrogen Receptor alpha / genetics
  • Estrogen Receptor alpha / physiology*
  • Estrogen Receptor beta / agonists
  • Estrogen Receptor beta / deficiency
  • Estrogen Receptor beta / genetics
  • Estrogen Receptor beta / physiology*
  • Female
  • Interleukin-10 / metabolism
  • Interleukin-6 / metabolism*
  • Lipopolysaccharides / pharmacology
  • Lymphocyte Activation / drug effects
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Ovariectomy
  • Phenols
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Shock, Hemorrhagic / drug therapy*
  • Shock, Hemorrhagic / immunology
  • Shock, Hemorrhagic / physiopathology
  • Spleen / blood supply
  • Spleen / injuries*
  • Spleen / pathology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / metabolism
  • Tumor Necrosis Factor-alpha / metabolism*
  • Wounds and Injuries / complications
  • Wounds and Injuries / drug therapy
  • Wounds and Injuries / immunology
  • Wounds and Injuries / physiopathology

Substances

  • Cytokines
  • Estrogen Receptor alpha
  • Estrogen Receptor beta
  • Interleukin-6
  • Lipopolysaccharides
  • Phenols
  • Pyrazoles
  • Tumor Necrosis Factor-alpha
  • 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol
  • Concanavalin A
  • Interleukin-10
  • Estradiol